Sanofi India Secures ₹52 Lakh GST Refund, Fights ₹11 Lakh Denial

Sanofi India has secured a GST refund of ₹52.08 lakh, but will contest the denial of ₹11.63 lakh by tax authorities.

Refund boost of ₹52.08 lakh; appeal on ₹11.63 lakh adds potential tax matter.

What happened

Sanofi India Ltd. received a refund order from the Assistant Commissioner of CGST, Vadodara. The company has been granted ₹52,07,841 (₹52.08 lakh) for periods between August 2014 and June 2017. This includes ₹33.97 lakh in principal and ₹18.11 lakh in interest.

However, tax authorities did not accept a claim of ₹11,62,853 (₹11.63 lakh). Sanofi India intends to file an appeal against this decision. The original refund application, which included a pre-deposit, was for ₹45,59,558 (₹45.60 lakh).

Why this matters

This partial refund provides an immediate, modest boost to Sanofi India's cash flow. The pending appeal signifies the company is pursuing the full amount it believes is owed, representing a potential future financial gain.

Company tax history

Sanofi India has a history of engaging with tax authorities and tax litigation in India. The company previously faced significant tax demands, including a retrospective tax controversy over the acquisition of Shantha Biotech, which was eventually settled.

More recently, the pharmaceutical firm has received multiple tax orders. These include a GST demand of ₹24.10 lakh for FY18-19 (received Dec 2025), a ₹26.50 crore income tax order in Jan 2025 for disallowed international transactions, and a ₹12.37 crore tax assessment for FY22-23 in March 2026. Sanofi India has indicated its intention to appeal these decisions.

What changes now

Sanofi India expects an immediate cash inflow of ₹52.08 lakh from the approved refund. The company's planned appeal means the ₹11.63 lakh is still under dispute, with its resolution pending. This situation highlights Sanofi India's active management of tax matters.

Risks to watch

The primary risk is that Sanofi India's appeal against the denied refund of ₹11.63 lakh may not be successful, potentially leading to the forfeiture of this claimed amount.

Peer context

Sanofi India operates in a sector where tax disputes are common. Peers like Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, and Cipla also navigate complex regulatory and tax environments. While this refund is minor, Sanofi India's history shows a pattern of engaging with tax authorities.

Financial context

As of December 31, 2024, Sanofi India's auditors reported pending litigations under direct and indirect tax laws with contingent liabilities of Rs. 2,911 million (₹291.1 crore).

What to track next

• The progress and final outcome of Sanofi India's appeal against the denied refund of ₹11.63 lakh.
• Any further updates or resolutions from the CGST authorities regarding the appeal.